Suppr超能文献

OPTN/SRTR 2022 年度数据报告:肾脏。

OPTN/SRTR 2022 Annual Data Report: Kidney.

机构信息

Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, MN; SSM Health Saint Louis University Hospital Transplant Center, Saint Louis University School of Medicine, St. Louis, MO.

Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, MN; Department of Pediatrics, University of Washington, Seattle, WA.

出版信息

Am J Transplant. 2024 Feb;24(2S1):S19-S118. doi: 10.1016/j.ajt.2024.01.012.

Abstract

The year 2022 had continued successes and challenges for the field of kidney transplantation, as the community adapted to ongoing surges of the COVID-19 pandemic and broader geographic organ distribution. The total number of kidney transplants in the United States reached a record count of 26,309, driven by continued growth in deceased donor kidney transplants (DDKTs). The total number of candidates listed for DDKT rose slightly in 2022 but remained below 2019 listing levels, with 12.4% of candidates having been waiting 5 years or longer. Following the height of the COVID-19 pandemic, pretransplant mortality in 2022 declined across age, race and ethnicity, sex, and blood type groups. Pretransplant mortality continued to vary substantially by donation service area. The proportion of deceased donor kidneys recovered but not used for transplant (nonuse rate) rose to a high of 26.7% overall, with greater nonuse of biopsied kidneys (39.8%), kidneys from donors aged 55 years or older (54.7%), and kidneys with a kidney donor profile index (KDPI) of 85% or greater (71.3%). Nonuse of kidneys from donors who are hepatitis C virus (HCV) antibody positive rose to 30.2% but only slightly exceeded that of HCV antibody-negative donors. Disparities in access to living donor kidney transplant (LDKT) persist, especially for non-White and publicly insured patients. Delayed graft function continues an upward trend and occurred in 26.3% of adult kidney transplants in 2022. Five-year graft survival after LDKT compared with DDKT was 90.0% versus 81.4% for recipients aged 18-34 years and 80.8% versus 67.8% for recipients aged 65 years or older, respectively. The total number of pediatric kidney transplants performed in 2022 decreased to 705, its lowest point in the past decade; 502 (71.2%) were DDKTs and 203 (28.8%) were LDKTs. Among pediatric recipients, LDKT remains low, with continued racial disparities. The rate of DDKT among pediatric candidates has decreased by almost 25% since 2011. Congenital anomalies of the kidney and urinary tract remain the leading primary kidney disease diagnosis among pediatric candidates with a reported diagnosis. Most pediatric deceased donor recipients received a kidney from a donor with a KDPI of less than 35%. The rate of delayed graft function was 5.8% in 2022 and has been stable over the past decade. Long-term graft survival continues to improve, with superior outcomes for living donor transplant recipients.

摘要

2022 年,肾脏移植领域取得了持续的成功和挑战,因为该领域适应了持续的 COVID-19 大流行和更广泛的地理器官分布。美国的肾脏移植总数达到了 26309 例的创纪录水平,这得益于已故供体肾脏移植(DDKT)的持续增长。2022 年,DDKT 的候选人数略有上升,但仍低于 2019 年的登记水平,其中 12.4%的候选者已经等待了 5 年或更长时间。在 COVID-19 大流行达到高峰后,2022 年各年龄段、种族和族裔、性别和血型组的移植前死亡率均有所下降。移植前死亡率继续因捐赠服务区的不同而有很大差异。未用于移植的已故供体肾脏的比例(未使用率)上升至 26.7%的高位,其中活检肾脏(39.8%)、55 岁或以上供体的肾脏(54.7%)和肾脏捐赠者概况指数(KDPI)为 85%或更高(71.3%)的肾脏的未使用率更高。丙型肝炎病毒(HCV)抗体阳性供体的肾脏未使用率上升至 30.2%,但仅略高于 HCV 抗体阴性供体的未使用率。活体供体肾脏移植(LDKT)的机会仍然存在差距,尤其是对于非白人患者和公共保险患者。延迟移植物功能障碍继续呈上升趋势,2022 年成人肾脏移植中有 26.3%发生延迟移植物功能障碍。与 DDKT 相比,18-34 岁和 65 岁或以上接受 LDKT 的患者的 5 年移植物存活率分别为 90.0%和 81.4%和 80.8%和 67.8%。2022 年进行的儿童肾脏移植总数降至 705 例,为过去十年中的最低点;502 例(71.2%)为 DDKT,203 例(28.8%)为 LDKT。在儿科受者中,LDKT 仍然很低,且存在持续的种族差异。自 2011 年以来,儿科候选者的 DDKT 率下降了近 25%。儿童候选者中,先天性肾和尿路畸形仍然是主要的肾脏疾病诊断,有报道称该诊断。大多数儿科已故供体受者接受的肾脏来自 KDPI 小于 35%的供体。2022 年,延迟移植物功能障碍的发生率为 5.8%,过去十年一直保持稳定。移植物长期存活率继续提高,活体供体移植受者的预后更好。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验